anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 228,421-228,450
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

228,421-228,450 of 303,780

filter-aware
30
The slide uses a stylized area chart to represent market segments and their respective valuations.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
32
The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
33
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
34
The slide uses a side-by-side comparison of two disease indications, each with a list of clinical outcomes and a bottom section showing relevant market competitors and patient incidence numbers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
35
The chart illustrates clinical trial efficacy data for NXC-201.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
36
Includes a complex biological pathway diagram and three supporting charts (penetration depth, accumulation over time, and apoptosis efficacy).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
37
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
38
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a comparative layout to position NXC-201 as a superior, one-time monotherapy against current multi-drug, weekly treatment regimens.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
41
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management of side effects.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
42
The slide highlights specific safety data points for Arcellx's product, likely for competitive benchmarking purposes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
43
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
44
The table compares clinical trial inclusion criteria across four different therapies, focusing on prior lines of therapy, toxicity recovery, ECOG status, and measurable disease definitions.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
45
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
46
The slide uses a bar chart to contrast the combined market size of two groups of drugs ($33.4bn vs $0.9bn).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
47
Slide contains three distinct data charts comparing IMX-110 against standard treatments in mouse models.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
48
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
49
Includes unpublished internal data alongside referenced Winograd et al. 2015 study.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
50
The slide compares two cohorts: Soft Tissue Sarcoma and Non-Sarcoma Cancers, using line charts for longitudinal change and bar charts for best response.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
51
The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
52
The chart on the left is a conceptual visualization rather than a standard data plot, emphasizing the 100% heavily pre-treated patient population.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a process flow diagram to illustrate the clinical development path for two different treatment regimens.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
54
Includes comparative size illustration of IMX-111 vs IgG antibody, and survival curve data.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
55
Includes two sets of charts: tumor volume over time and survival curves for two different cancer models.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a mix of mechanism-of-action diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
60
The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
61
The slide uses a 3-pillar framework to explain the platform, then maps these to specific drug candidates with detailed mechanism-of-action descriptions.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
62
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit